[go: up one dir, main page]

ATE426597T1 - Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel - Google Patents

Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel

Info

Publication number
ATE426597T1
ATE426597T1 AT05708360T AT05708360T ATE426597T1 AT E426597 T1 ATE426597 T1 AT E426597T1 AT 05708360 T AT05708360 T AT 05708360T AT 05708360 T AT05708360 T AT 05708360T AT E426597 T1 ATE426597 T1 AT E426597T1
Authority
AT
Austria
Prior art keywords
glucocinase
benzamide derivatives
activate agents
activate
agents
Prior art date
Application number
AT05708360T
Other languages
English (en)
Inventor
Craig Johnstone
Darren Mckerrecher
Kurt Pike
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34890799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE426597(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0403593A external-priority patent/GB0403593D0/en
Priority claimed from GB0413386A external-priority patent/GB0413386D0/en
Priority claimed from GB0423039A external-priority patent/GB0423039D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE426597T1 publication Critical patent/ATE426597T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
AT05708360T 2004-02-18 2005-02-15 Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel ATE426597T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0403593A GB0403593D0 (en) 2004-02-18 2004-02-18 Compounds
GB0413386A GB0413386D0 (en) 2004-06-16 2004-06-16 Compounds
GB0423039A GB0423039D0 (en) 2004-10-16 2004-10-16 Compounds

Publications (1)

Publication Number Publication Date
ATE426597T1 true ATE426597T1 (de) 2009-04-15

Family

ID=34890799

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05708360T ATE426597T1 (de) 2004-02-18 2005-02-15 Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel

Country Status (17)

Country Link
US (2) US20080280872A1 (de)
EP (2) EP1718624B1 (de)
JP (1) JP2007523142A (de)
KR (1) KR20070007103A (de)
AR (1) AR047678A1 (de)
AT (1) ATE426597T1 (de)
AU (1) AU2005214132B9 (de)
BR (1) BRPI0507746A (de)
CA (1) CA2554310A1 (de)
DE (1) DE602005013491D1 (de)
ES (1) ES2322709T3 (de)
IL (1) IL177216A0 (de)
NO (1) NO20063452L (de)
RU (1) RU2392275C2 (de)
TW (1) TW200602028A (de)
UY (1) UY28756A1 (de)
WO (1) WO2005080359A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
PE20050194A1 (es) 2003-02-13 2005-04-23 Banyu Pharma Co Ltd Derivados de piridina-2-carboxamida como activadores de glucoquinasa
MXPA05009059A (es) * 2003-02-26 2005-10-19 Banyu Pharma Co Ltd Derivados de heteroarilcarbamoilbenceno.
US20080280872A1 (en) * 2004-02-18 2008-11-13 Craig Johnstone Benzamide Derivatives and Their Use as Glucokinase Activating Agents
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
GB0423044D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
KR20070085371A (ko) * 2004-10-16 2007-08-27 아스트라제네카 아베 페녹시 벤즈아미드 화합물의 제조 방법
GB0423042D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Chemical process
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
NZ575512A (en) * 2005-07-09 2009-11-27 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
EP1931337B1 (de) 2005-09-29 2013-10-23 Sanofi Phenyl- und pyridinyl-1,2,4-oxadiazolon-derivate, verfahren zu ihrer herstellung und ihre verwendung als pharmazeutika
JP2009515997A (ja) * 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
TW200738621A (en) * 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
AU2007278261A1 (en) 2006-07-24 2008-01-31 F. Hoffmann-La Roche Ag Pyrazoles as glucokinase activators
SA07280576B1 (ar) * 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
AR064625A1 (es) * 2006-12-21 2009-04-15 Astrazeneca Ab Forma cristalina de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-[(1-metiletil)oxi]-n-1h-pirazol-3-ilbenzamida
CN101808995A (zh) 2007-07-27 2010-08-18 百时美施贵宝公司 新颖的葡糖激酶激活剂及其使用方法
BRPI0818348A2 (pt) 2007-10-09 2015-04-07 Merck Patent Ges Mit Beschränkter Haftung Derivados de n-(pirazol-3-il)-benzamida como ativadores de glicocinase
BRPI0908124A2 (pt) 2008-02-06 2015-08-04 Daiichi Sankyo Co Ltd Composto, ativador de glucoquinase, composição farmacêutica, uso de um composto ou sal farmacologicamente aceitavél do mesmo, e, métodos de ativação da glucoquinase, e para tratar e/ou prevenir uma doença
US20110009437A1 (en) * 2008-02-27 2011-01-13 Merck Patent Gesellschaft Mit Beschrankter Haftung Carboxamide-heteroaryl derivatives for the treatment of diabetes
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
MX2011001333A (es) 2008-08-04 2011-03-15 Astrazeneca Ab Derivados de pirazolo [3, 4] pirimidin-4-ilo y sus usos para tratar la diabetes y obesidad.
WO2010082601A1 (ja) * 2009-01-16 2010-07-22 第一三共株式会社 新規２，５－二置換ピロール誘導体
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
GB0902406D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
AR076221A1 (es) * 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
JPWO2010128595A1 (ja) * 2009-05-07 2012-11-01 富士フイルムＲｉファーマ株式会社 放射性ヨウ素標識イミダゾピリジン誘導体の製造法
WO2010150280A1 (en) 2009-06-22 2010-12-29 Cadila Healthcare Limited Disubstituted benzamide derivatives as glucokinase (gk) activators
EP2459554B1 (de) 2009-07-31 2013-09-18 Cadila Healthcare Limited Substituierte benzamidderivate als glucokinase (gk)-aktivatoren
JPWO2011071095A1 (ja) * 2009-12-11 2013-04-22 アステラス製薬株式会社 ベンズアミド化合物
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
WO2011122458A1 (ja) * 2010-03-29 2011-10-06 第一三共株式会社 含窒素芳香環化合物

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2750393A (en) * 1954-12-01 1956-06-12 Sterling Drug Inc Iodinated 5-henzamidotetrazoles and preparation thereof
US2967194A (en) * 1958-05-15 1961-01-03 Pennsalt Chemicals Corp 4-trifluoromethylsalicylamides
GB1400540A (en) * 1972-12-06 1975-07-16 Smith Kline French Lab Salicylamides and compositions thereof
US4009174A (en) * 1972-12-08 1977-02-22 The Boots Company Limited Esters of substituted nicotinic acids
GB1437800A (en) * 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
GB1561350A (en) * 1976-11-05 1980-02-20 May & Baker Ltd Benzamide derivatives
FR2344284A1 (fr) * 1976-03-17 1977-10-14 Cerm Cent Europ Rech Mauvernay Nouveaux composes tricycliques a cycle furannique et leur application comme antidepresseurs
US4474792A (en) * 1979-06-18 1984-10-02 Riker Laboratories, Inc. N-Tetrazolyl benzamides and anti-allergic use thereof
FR2493848B2 (fr) * 1980-11-07 1986-05-16 Delalande Sa Nouveaux derives des nor-tropane et granatane, leur procede de preparation et leur application en therapeutique
JPS59139357A (ja) * 1983-01-28 1984-08-10 Torii Yakuhin Kk アミジン誘導体
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
US5258407A (en) * 1991-12-31 1993-11-02 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
US5466715A (en) * 1991-12-31 1995-11-14 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
US5273986A (en) * 1992-07-02 1993-12-28 Hoffmann-La Roche Inc. Cycloalkylthiazoles
US5661153A (en) * 1994-07-19 1997-08-26 Japan Energy Corporation 1-arylpyrimidine derivatives and pharmaceutical use thereof
US5510478A (en) * 1994-11-30 1996-04-23 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5672750A (en) * 1994-12-16 1997-09-30 Eastman Chemical Company Preparation of aromatic amides from carbon monoxide, an amine and an aromatic chloride
US5849735A (en) * 1995-01-17 1998-12-15 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5712270A (en) * 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
TW429241B (en) 1996-09-26 2001-04-11 Sumitomo Pharma Nitrone derivatives
AUPO395396A0 (en) * 1996-12-02 1997-01-02 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
FR2757852B1 (fr) * 1996-12-31 1999-02-19 Cird Galderma Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations
EP0995742A4 (de) * 1997-06-27 2004-08-25 Fujisawa Pharmaceutical Co Sulfonamidverbindungen und ihre medizinische verwendung
DE69826286T2 (de) * 1997-06-27 2005-11-24 Fujisawa Pharmaceutical Co., Ltd. Derivate mit einem aromatischen ring
US6613942B1 (en) * 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
ES2317688T3 (es) * 1998-01-29 2009-04-16 Amgen Inc. Moduladores ppar-gamma.
DE19816780A1 (de) * 1998-04-16 1999-10-21 Bayer Ag Substituierte 2-Oxo-alkansäure-[2-(indol-3-yl)-ethyl]amide
GB9811969D0 (en) * 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
US6197798B1 (en) * 1998-07-21 2001-03-06 Novartis Ag Amino-benzocycloalkane derivatives
MXPA01009814A (es) 1999-03-29 2002-04-24 Hoffmann La Roche Activadores de la glucoquinasa.
US6610846B1 (en) * 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
RU2242469C2 (ru) * 1999-03-29 2004-12-20 Ф.Хоффманн-Ля Рош Аг Активаторы глюкокиназы
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
WO2001035950A2 (en) * 1999-11-18 2001-05-25 Centaur Pharmaceuticals, Inc. Benzamide therapeutics and methods for treating inflammatory bowel disease
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
DK1259485T3 (da) * 2000-02-29 2006-04-10 Millennium Pharm Inc Benzamider og beslægtede inhibitorer for faktor Xa
US6534651B2 (en) * 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
KR100502033B1 (ko) * 2000-05-03 2005-07-25 에프. 호프만-라 로슈 아게 알키닐 페닐 헤테로방향족 글루코키나제 활성제
EP1336605B1 (de) * 2000-11-22 2006-04-12 Astellas Pharma Inc. Substituierte phenolderivate und deren salze als hemmstoffe von koagulations faktor x
AU2002221902B2 (en) * 2000-12-06 2006-11-23 F. Hoffmann-La Roche Ag Fused heteroaromatic glucokinase activators
EP1344525A4 (de) * 2000-12-22 2005-05-25 Ishihara Sangyo Kaisha Anilinderivate oder ihre salze und diese enthaltende zytokinproduktion-inhibitoren
SE0102299D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102300D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
EP1431267A4 (de) * 2001-08-09 2004-12-22 Ono Pharmaceutical Co Carbonsäurederivatverbindungen und arzneimittel, die diese verbindung als wirkstoff enthalten
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
DE10161765A1 (de) * 2001-12-15 2003-07-03 Bayer Cropscience Gmbh Substituierte Phenylderivate
US20030171411A1 (en) 2001-12-21 2003-09-11 Kodra Janos Tibor Amide derivatives as therapeutic agents
EP1496052B1 (de) 2002-03-26 2009-08-05 Banyu Pharmaceutical Co., Ltd. Neue aminobenzamidderivate
AU2003232204B8 (en) 2002-04-26 2009-07-30 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
WO2004002481A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
EP1541563A4 (de) * 2002-07-10 2007-11-07 Ono Pharmaceutical Co Ccr4-antagonist und dessen medizinische verwendung
GB0226930D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226931D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
MXPA05009059A (es) * 2003-02-26 2005-10-19 Banyu Pharma Co Ltd Derivados de heteroarilcarbamoilbenceno.
GB0325402D0 (en) * 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
US20050171172A1 (en) * 2003-11-13 2005-08-04 Ambit Biosciences Corporation Amide derivatives as PDGFR modulators
GB0327761D0 (en) * 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
GB0327760D0 (en) * 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
GB0328178D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Compounds
US20080280872A1 (en) * 2004-02-18 2008-11-13 Craig Johnstone Benzamide Derivatives and Their Use as Glucokinase Activating Agents
CA2554686A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Compounds
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
TWI400232B (zh) * 2004-09-13 2013-07-01 Ono Pharmaceutical Co 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑
GB0423044D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
KR20070085371A (ko) * 2004-10-16 2007-08-27 아스트라제네카 아베 페녹시 벤즈아미드 화합물의 제조 방법
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
US20080234273A1 (en) * 2005-07-09 2008-09-25 Mckerrecher Darren Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes
NZ575512A (en) * 2005-07-09 2009-11-27 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
JP2009508832A (ja) * 2005-09-16 2009-03-05 アストラゼネカ アクチボラグ グルコキナーゼ活性化剤としてのヘテロ二環式化合物
TW200738621A (en) * 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
TW200825063A (en) * 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
SA07280576B1 (ar) * 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
AR064625A1 (es) * 2006-12-21 2009-04-15 Astrazeneca Ab Forma cristalina de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-[(1-metiletil)oxi]-n-1h-pirazol-3-ilbenzamida

Also Published As

Publication number Publication date
NO20063452L (no) 2006-10-31
WO2005080359A1 (en) 2005-09-01
UY28756A1 (es) 2005-09-30
AU2005214132B9 (en) 2009-06-25
ES2322709T3 (es) 2009-06-25
TW200602028A (en) 2006-01-16
RU2392275C2 (ru) 2010-06-20
AU2005214132B2 (en) 2009-05-07
RU2006130684A (ru) 2008-03-27
AR047678A1 (es) 2006-02-01
EP1718624A1 (de) 2006-11-08
CA2554310A1 (en) 2005-09-01
DE602005013491D1 (de) 2009-05-07
AU2005214132A1 (en) 2005-09-01
US20110034432A1 (en) 2011-02-10
US20080280872A1 (en) 2008-11-13
EP1718624B1 (de) 2009-03-25
HK1096092A1 (en) 2007-05-25
BRPI0507746A (pt) 2007-07-10
JP2007523142A (ja) 2007-08-16
KR20070007103A (ko) 2007-01-12
EP2048137A1 (de) 2009-04-15
IL177216A0 (en) 2006-12-10

Similar Documents

Publication Publication Date Title
ATE426597T1 (de) Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel
DE602005004144D1 (de) Octahydropyrroloä3,4-cüpyrrolderivate und deren verwendung als antivirale mitteln
ATE543825T1 (de) Spiro-oxindolverbindungen und ihre verwendungen als therapeutische mittel
ATE378338T1 (de) Pyrrolopyridinderivate und deren verwendung als crth2-antagonisten
DE602004021904D1 (de) Gyraseinhibitoren und deren verwendungen
DE60321043D1 (de) Biphenylderivate und deren verwendung als fungizide
DE60308998D1 (de) N-aryl-2-oxazolidinon-5-carbonsäureamide und deren derivate und deren verwendung als antibakterielle mittel
ATE502925T1 (de) 6-alkyl- oder alkenyl-4-aminopicolinate und deren verwendung als herbizide
ATE472546T1 (de) 5-heteroarylthiazole und deren verwendung als pi3k-inhibitoren
DE602005001123D1 (de) Wässrige Emulsion und deren Verwendung
EP1746902A4 (de) Multilektin-affiniätschromatografie und verwendung dafür
DE602006020330D1 (de) Pyridazinverbindung und deren verwendung
ATE472549T1 (de) Octahydropyrroloä3,4-cüpyrrolderivate und ihre verwendung als antivirale mittel
EP1469860A4 (de) Antikrebskombination und deren verwendung
DE502005007106D1 (de) Substituierte phenylaminothiazole und ihre verwendung
ATE511507T1 (de) Piperidinylcarbonylpyrrolidine und deren verwendung als melanocortinagonisten
DE602004028700D1 (de) Kosmetische Zusammensetzungen und deren Verwendung
ATE482957T1 (de) Arylessigsäure- und esterderivate und deren verwendung als entzündungshemmende mittel
DE602004008668D1 (de) Benzoxazinderivate und deren verwendungen
DE602006018166D1 (de) Polyrotaxanhaltige lösung und verwendung davon
DE602005009988D1 (de) Härtbare Zusammensetzung und deren Verwendung
ATE396185T1 (de) Substituierte 4-alkyl- und 4- alkanoylpiperidinderivate und deren verwendung als neurokininantagonisten
DE602005022060D1 (de) Diaminoalkohole und deren verwendung als renininhibitoren
ATE517098T1 (de) Acylaminothiazolderivate und deren verwendung als beta-amyloid-inhibitoren
DE60311277D1 (de) Benzotriazabicyclische derivate und deren verwendung als beta-lactamaseinhibitoren und antibakterielle mittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties